Global News

Galen acquires Synera topical patch

Friday, July 12, 2013 02:09 PM

Galen, a Northern Ireland-based pharmaceutical company, has acquired Synera (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, a wholly-owned subsidiary of Nuvo Research. Synera is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions. Galen U.S., a wholly owned subsidiary of Galen, will market and sell Synera in the U.S.

More... »

Accenture launches Accelerated R&D Services

Friday, July 12, 2013 02:05 PM

Accenture, a global management consulting, technology services and outsourcing company, has launched the Accenture Accelerated R&D Services, a business service focused on delivering streamlined and integrated R&D functions to help pharmaceutical companies bring new medications to patients using a more collaborative approach. Accenture is investing more than $200 million to deliver this fully-integrated, technology-enabled global business service.

More... »

ERT’s SITEpro Tablet authorized to measure QoL

Friday, July 12, 2013 02:01 PM

ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, is authorized to provide validated, electronic versions of commonly used health-related Quality of Life (QoL) questionnaires on SITEpro Tablet—its patient data collection system for use at sites. The questionnaires, developed by professor Elizabeth Juniper, measure QoL among patients in clinical trials of asthma and rhinoconjunctivitis treatments.

More... »

Former Millennium CEO Deborah Dunsire joins EnVivo as president and CEO

Friday, July 12, 2013 01:57 PM

EnVivo Pharmaceuticals, developing a range of novel therapies for central nervous system (CNS) diseases, has named Deborah Dunsire, M.D., president and chief executive officer. She also joins the company's board of directors. Dunsire brings more than 25 years of scientific, clinical, operational and commercial experience and biological and pharmaceutical industry leadership to EnVivo.

More... »

China investing billions in bid to catch up with Western pharma

Friday, July 12, 2013 01:55 PM

China's biomedical sector is transforming itself from a manufacturing base to an innovation hub, investing billions of dollars and setting up innovation centers in a bid to catch up with the west by the end of the 12th Five-Year Plan, according to Lux Research, which provides advice and ongoing intelligence for emerging technologies.

More... »

MannaResearch acquires Kells Medical Research Group

Friday, July 12, 2013 09:46 AM

Montreal-based MannaResearch, a group of independent clinical research centers, has announced acquired Kells Medical Research Group, a Montreal-based clinical investigator site.

More... »

Amgen, Servier announce product collaboration

Thursday, July 11, 2013 01:01 PM

Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have entered a collaboration agreement leveraging each company's commitment to cardiovascular disease.

More... »

Forma Therapeutics, CRT collaborate

Thursday, July 11, 2013 12:11 PM

Forma Therapeutics and Cancer Research Technology (CRT), the commercialization company of Cancer Research U.K., have announced a research initiative to discover tools, technologies and therapeutic drug candidates against a variety of protein homeostasis regulators called deubiquitinating enzymes (DUBs).

More... »

Schrödinger and ChemAxon extend partnership

Thursday, July 11, 2013 09:30 AM

Schrödinger, a drug discovery solutions company, and ChemAxon, a provider of cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries, have extended their partnership agreement for another five years. ChemAxon will provide the JChem chemistry engine as well as Marvin sketching and rendering functionality to Schrödinger's enterprise informatics platform, Seurat.

More... »

Loxo Oncology, Array BioPharma in license, collaboration agreement

Thursday, July 11, 2013 09:10 AM

Loxo Oncology, a biopharmaceutical company established and funded by Aisling Capital, and Array BioPharma have announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. 

More... »